Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis

• Published in: Molecular metabolism (Germany) Vol. 89; p. 102022
• Main Authors: Guan, Canghai, Zou, Xinlei, Yang, Chengru, Shi, Wujiang, Gao, Jianjun, Ge, Yifei, Xu, Zhaoqiang, Bi, Shaowu, Zhong, Xiangyu
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-11-2024; Elsevier
• Subjects: Lipid metabolism; Mcl-1; Metabolic-associated fatty liver disease; Mitochondrial membrane permeability; PNPT1; PPARα; Mcl-1; PNPT1; Metabolic-associated fatty liver disease; Lipid metabolism; Mitochondrial membrane permeability; PPARα
• ISSN: 2212-8778; 2212-8778
• DOI: 10.1016/j.molmet.2024.102022

Metabolic-associated fatty liver disease (MAFLD) represents one of the most prevalent chronic liver conditions worldwide, but its precise pathogenesis remains unclear. This research endeavors to elucidate the involvement and molecular mechanisms of polyribonucleotide nucleotidyltransferase 1 (PNPT1) in the progression of MAFLD.
The study employed western blot and qRT-PCR to evaluate PNPT1 levels in liver specimens from individuals diagnosed with MAFLD and in mouse models subjected to a high-fat diet. Cellular studies investigated the effects of PNPT1 on lipid metabolism, apoptosis, and mitochondrial stability in hepatocytes. Immunofluorescence was utilized to track the subcellular movement of PNPT1 under high lipid conditions. RNA immunoprecipitation and functional assays were conducted to identify interactions between PNPT1 and Mcl-1 mRNA. The role of PPARα as an upstream transcriptional regulator of PNPT1 was investigated. Recombinant adenoviral vectors were utilized to modulate PNPT1 expression in vivo.
PNPT1 was found to be markedly reduced in liver tissues from MAFLD patients and HFD mice. In vitro, PNPT1 directly regulated hepatic lipid metabolism, apoptosis, and mitochondrial stability. Under conditions of elevated lipids, PNPT1 relocated from mitochondria to cytoplasm, modifying its physiological functions. RNA immunoprecipitation revealed that the KH and S1 domains of PNPT1 bind to and degrade Mcl-1 mRNA, which in turn affects mitochondrial permeability. The transcriptional regulator PPARα was identified as a significant influencer of PNPT1, impacting both its expression and subsequent cellular functions. Alterations in PNPT1 expression were directly correlated with the progression of MAFLD in mice.
The study confirms the pivotal function of PNPT1 in the development of MAFLD through its interactions with Mcl-1 and its regulatory effects on lipid metabolism and mitochondrial stability. These insights highlight the intricate association between PNPT1 and MAFLD, shedding light on its molecular pathways and presenting a potential new therapeutic avenue for MAFLD management.
[Display omitted]
•PNPT1 expression is significantly downregulated in liver from MAFLD patients and HFD mouse models.•PNPT1 regulates hepatic lipid metabolism, apoptosis, and mitochondrial stability in hepatocytes.•Under high lipid conditions, PNPT1 moves from mitochondria to cytoplasm, exacerbating MAFLD via Mcl-1 interaction.•PPARα acts as an upstream transcriptional regulator of PNPT1, influencing its role in MAFLD pathogenesis.